Skip to main content
. Author manuscript; available in PMC: 2017 Jul 7.
Published in final edited form as: Clin Cancer Res. 2015 Oct 21;22(6):1341–1347. doi: 10.1158/1078-0432.CCR-15-1441

Table 2.

Summary of progression events defined by various cut points of relative increase in sum of lesion size, and correlation with OS among patients randomized to vemurafenib in the BRIM3 study (n = 325)

From baseline
From nadir
Without new lesions
With new lesions
Without new lesions
With new lesions
Number of events Correlation with OS Number of events Correlation with OS Number of events Correlation with OS Number of events Correlation with OS
Relative increase
 Any 81 0.341 (0.077) 221 0.518 (0.042) NA NA NA NA
 25% 43 0.443 (0.099) 201 0.608 (0.039) 145 0.521 (0.049) 252 0.564 (0.036)
 50% 18 NA 192 0.655 (0.034) 96 0.605 (0.053) 227 0.614 (0.034)
 100% 8 NA 188 0.664 (0.035) 57 0.513 (0.087) 212 0.630 (0.035)

Abbreviation: NA, not assessable.